A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

Inclusion Criteria:

   - Willing and able to give consent/assent

   - Clinical diagnosis of epidermolysis bullosa

   - Confirmation of diagnosis (either DDEB or RDEB) by genetic testing including COL7A1.

   - Age: 2 months of age and older at the time of informed consent/assent

   - Women of childbearing age must be willing to use reliable birth control method
   throughout the treatment duration and for 3 months following the last treatment
   application

Exclusion Criteria:

   - Diseases or conditions that could interfere with the assessment of safety of the study
   treatment and compliance of the participant with study visits/procedures, as
   determined by the Investigator

   - Pregnant or nursing women

   - Active infection in the area that will undergo administration, that the Investigator
   believes will negatively impact the IP application

   - Known allergy to any of the constituents of the product

   - Concurrent skin transplant or mesh skin grafting; if the participant is currently
   having transplantation or grafting surgeries they must wait until the transplant has
   begun to heal and the graft has absorbed prior to initiating B-VEC therapy

   - Participation in an interventional gene therapy clinical trial within the past three
   (3) months (not including B-VEC administration)